CAS: 548-37-8; Methyl (1S,4As,7S,7Ar)-7-Methyl-5-Oxo-1-(((2S,3R,4S,5S,6R)-3,4,5-Trihydroxy-6-(Hydroxymethyl)Tetrahydro-2H-Pyran-2-yl)Oxy)-1,4A,5,6,7,7A-Hexahydrocyclopenta[c]Pyran-4-Carboxylate

专利信息

专利号:US-2023135239-A1
优先权日:2021-11-04
标 题 :Drug for treating severe acute respiratory syndrome caused by coronavirus and complications thereof and use of the drug
发明人：YU WENQIANG; LI ZHENYAN; XU JIANQING; LI WEI; LIAN CHENG
权利人:SHANGHAI PUBLIC HEALTH CLINICAL CT; SHANGHAI YIZHE BIOTECHNOLOGY CO LTD
摘要:The present invention discloses a drug for treating severe acute respiratory syndrome caused by coronavirus and the complications thereof and the use of the drug, and specifically the use of an agent in the preparation of a drug for treating severe acute respiratory syndrome caused by coronavirus and the complications thereof. The above-mentioned agent is at least one of hyaluronic acid synthesis inhibitor, hyaluronidase, hyaluronidase inhibitor, hyaluronic acid receptor inhibitor, and anticoagulant. The present invention is based on the discovery of an important pathogenic mechanism of severe acute respiratory syndrome-related coronavirus 2 that a sequence homologous to human in severe acute respiratory syndrome-related coronavirus 2, named HIS (Human Insert Sequence), can specifically activate hyaluronic acid synthase HAS and other inflammatory factors, and then it is found from clinical samples that the content of hyaluronic acid in the serum of a patient with severe COVID-19 is significantly higher than that in a patient with mild COVID-19. The above-mentioned agent is used for the first time for treating coronavirus and complications, and it is verified that a hyaluronic acid synthesis inhibitor can reduce the content of hyaluronic acid, thus the adjustment of hyaluronic acid level has good application value in the treatment and/or prevention of conditions caused by coronavirus.